Literature DB >> 11844842

Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide.

N Abramson, P K Stokes, Mathew Luke, Alan R Marks, Jeffrey M Harris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11844842     DOI： 10.1200/JCO.2002.20.4.1147

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

Review 1.  Targeted therapies for gynecologic malignancies.

Authors:  Johnny Hyde; D Scott McMeekin
Journal:  Curr Treat Options Oncol       Date:  2005-03

2.  Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer.

Authors:  Perry Shen; Christopher R Thomas; Joyce Fenstermaker; Mebea Aklilu; Thomas P McCoy; Edward A Levine
Journal:  J Gastrointest Cancer       Date:  2014-09

Review 3.  Tumor angiogenesis and molecular target therapy in ovarian carcinomas.

Authors:  Masatsugu Ueda; Yoshito Terai; Koji Kanda; Masanori Kanemura; Mikio Takehara; Hikari Futakuchi; Hiroyuki Yamaguchi; Masayuki Yasuda; Koji Nishiyama; Minoru Ueki
Journal:  Hum Cell       Date:  2005-03       Impact factor: 4.174

4.  A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

Authors:  D Scott McMeekin; Michael W Sill; Doris Benbrook; Kathleen M Darcy; Deborah J Stearns-Kurosawa; Lynne Eaton; S Diane Yamada
Journal:  Gynecol Oncol       Date:  2007-02-15       Impact factor: 5.482

5.  Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature.

Authors:  Clemens B Tempfer; Beate Schultheis; Ziad Hilal; Askin Dogan; Günther A Rezniczek
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.